What a 38% rise in coupling-reagent prices does to a 15 mg vial
Follow the resin, not the catalogue.
May 2024 — Vol. 1, No. 5
Page 3 of 4 of this archive, newest first.
Also filed — page 3
the rolling newsroom, May 2024Turkey caps liraglutide prescribing to 8 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
A supplier suspends shipping to Mexico after 12 consecutive customs detentions
The route did not close because of a rule about peptides.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
New Zealand declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
PIONEER 6 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.
New Zealand caps semaglutide prescribing to 13 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What changed at ERP in May, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Australia health authority warns on falsified liraglutide pens
Reported from the analysis, not from a warning notice.
The consolidator trading as Meridian Freight Partners closes after 14 years
A proper account of an operation that existed, and of what closing it cost.
The 22-day notice: how a compounding wind-down works in Norway
The document is four pages. Three of them are about dates.
What the new Australia guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
The online reseller trading as Adamant Research Supply enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
A supplier suspends shipping to Turkey after 22 consecutive customs detentions
The route did not close because of a rule about peptides.
TRIUMPH-1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The relabeller trading as Vantris Bio closes after 8 years
A proper account of an operation that existed, and of what closing it cost.
What the new France guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What a 16% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Calder Vale Peptides of Skipton closes after 11 years
A proper account of an operation that existed, and of what closing it cost.
Poland declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
SGN declines, for the 12th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
South Korea pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
Calder Vale Peptides of Skipton enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
PeptideMeter result on a Changsha liraglutide lot lands 3.8 points below the supplier’s figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
STEP 2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Turkey health authority warns on falsified tirzepatide pens
Reported from the analysis, not from a warning notice.
Independent analysis puts a Homopeptide cagrilintide lot at 98.1%, against 94.7% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.